FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products

  • Recommend
  • Tweet
  • Print
  • Email

Additional Resources

Deck: 
Comparative analytical, nonclinical, and clinical studies are necessary to protect patient safety
Teaser: 

In this presentation, BIO urges the Food and Drug Administration to prioritize patient safety and incentives for innovation at a public hearing on biosimilars.

In this presentation, BIO urges the Food and Drug Administration to prioritize patient safety and incentives for innovation at a public hearing on biosimilars.

Main Image: 
image/jpeg iconfda_building_2.jpg [3]
Thumbnail Image: 
image/jpeg iconfda_building_2.jpg [4]
Additional Resources: 
Download the Presentation (PDF) [2]
Hide Related Contenet: 
Show
Hide Date: 
Show
Show Author Info?: 
Show Author Info?